COVID-19 Vaccination Uptake Among Individuals With Immune-mediated Inflammatory Diseases in Ontario, Canada, Between December 2020 and October 2021: A Population-based Analysis

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Figure 1.
Cumulative percentage of each population with at least 1 dose by October 3, 2021.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Cumulative percentage of each population with 2 doses by October 3, 2021.

Table 1.

Overall summary of first and second vaccine doses administered to the study population as of October 3, 2021.

Any Vaccine Type	General Population, n = 12,435,914	RA, n = 138,304	AS, n = 28,509	PsA, n = 17,646	PsO, n = 182,319	IBD, n = 108,792
Received at least 1 dose	10,208,667 (82.1)	122,893 (88.9)	24,911 (87.4)	15,995 (90.6)	159,220 (87.3)	94,613 (87.0)
Vaccine product of 1st dose^{^a}
BNT162b2	7,384,130 (72.3)	89,816 (73.1)	17,650 (70.9)	11,361 (71.0)	113,523 (71.3)	67,535 (71.4)
mRNA-1273	1,958,127 (19.2)	23,225 (18.9)	4,564 (18.3)	2,746 (17.2)	28,655 (18.0)	17,604 (18.6)
ChAdOx1 nCoV-19	862,543 (8.4)	9,831 (8.0)	2,689 (10.8)	1,886 (11.8)	17,011 (10.7)	9,456 (10.0)
Received 2 doses	9,694,968 (78.0)	119,198 (86.2)	24,082 (84.5)	15,556 (88.2)	153,521 (84.2)	91,187 (83.8)
Interval between 2 doses, days	60 (44–76)	70 (54–83)	64 (50–78)	67 (54–79)	65 (50–79)	64 (49–78)
Individuals ≥ 40 days overdue for 2nd dose^{^b}	237,665 (2.4)	2,280 (1.9)	412 (1.7)	256 (1.6)	2,827 (1.8)	1,724 (1.9)

Values are expressed as n (%) or median (IQR).
↵^aIn total, the vaccine type was another product or unknown vaccine product in 3867 individuals.
↵^bPotential vaccine dropouts who failed to complete the 2-dose series. AS: ankylosing spondylitis; IBD: inflammatory bowel disease; PsA: psoriatic arthritis; PsO: psoriasis; RA: rheumatoid arthritis.